Introduction {#Sec1}
============

Sebaceous carcinoma (SC) is a rare, aggressive cancer that has a predilection for the periorbital region, but can originate from extraocular sites, albeit mainly within the head region \[[@CR1]\]. Geographical variation is significant, with the incidence around 0.41 per million in UK, 0.65 per 100,000 in Canada, whereas in China it represents almost one-third of the malignant eyelid workload and is second to basal cell carcinoma (BCC) in frequency \[[@CR2]--[@CR4]\]. In Japan, one study found that the rate of SC equaled that of BCC \[[@CR5]\]. SC has two broad macroscopic presentations, namely nodular (local) or pagetoid (spreading). Misdiagnosis is common, often labeled as a benign chalazion in its nodular form or conjunctivitis in the conjunctival, pagetoid type (Supplementary Fig. S[1](#Fig5){ref-type="supplementary-material"}). Thus, it is described as a masquerading lesion with delays in diagnosis often greater than a year. Pagetoid expansion of the skin or conjunctiva carries a higher risk of orbital exenteration \[[@CR6]\]. Despite aggressive treatment, there is a high recurrence rate and metastasis often occurs via the lymphatics to the cervical lymph nodes \[[@CR7]\]. Mortality rates were once very high at 29%, but there is a significant range depending on which treatment modality is employed and can be as good as 6% in a center of excellence \[[@CR8]--[@CR10]\]. Prognosis depends on the size of the initial tumor and margin removed with a higher risk of recurrence seen with 1-3 mm margin versus 5 mm; however, achieving such a margin if the tumor is within the orbit is almost impossible \[[@CR11], [@CR12]\]. Staged excision using margin control may also improve removal of the tumor.

Hedgehog (Hh) signaling is essential during embryogenesis, and is down-regulated in most adult cells with transient expression in some adult tissues including brain, testis, and hair follicle \[[@CR13], [@CR14]\]. Hh signaling occurs via a cell membrane receptor complex that includes the proteins Patched (PTCH1) and Smoothened (SMO). In the absence of a Hh signal, PTCH1 inhibits the activation of SMO and subsequent downstream signaling. In the presence of Hh, the repressive action of PTCH1 on SMO is removed and the downstream pathway is mediated via the glioma-associated zinc transcription factors, Gli1 and Gli2, which translocate to the nucleus and activate Hh-target genes \[[@CR15]\]. Pathological activation of Hh signaling occurs in a variety of cancers, including BCC, prostate cancer, upper gastrointestinal tumors, a subset of small cell lung carcinoma and pancreatic ductal adenocarcinoma (Supplementary Table S[1](#MOESM2){ref-type="media"}) \[[@CR16]--[@CR20]\]. Genetic variants in Hh signaling are seen in up to 90% of sporadic BCC and many demonstrate Gli1 overexpression \[[@CR19], [@CR21]\].

The behavior of solid tumors is not restricted to the tumor borders delineated on microscopy; the surrounding non-malignant microenvironment, termed stroma, has been shown to play a key role in local spread \[[@CR22]\]. During embryogenesis, Hh signaling plays an important role in communication between epithelial tissue and surrounding stroma in a number of tissues in order to promote growth and differentiation of the stroma. For instance, urogenital epithelium utilizes Hh signaling to promote surrounding mesenchymal tissue to develop into the prostate gland \[[@CR23]\]. Reactivation of this paracrine phenomenon of Hh signaling has been shown in prostate cancer stroma and the tumor regulates the proliferation of adjacent non-malignant epithelium \[[@CR24]\]. Studies in ovarian cancer have highlighted the importance of the changes in the stroma that confer a poorer prognosis \[[@CR22], [@CR25]\] and the promotion of local invasion in morphoeic BCC has been demonstrated by modulating the stromal milieu \[[@CR26]\]. In this study, we examined the role of the canonical Hh pathway in both the SC tumor and surrounding apparently normal stroma by comparing it to nodular BCC (nBCC), a known Hh implicated tumor.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

This study obtained national ethics committee approval (REC reference 14/NW/1080) and adhered to the tenets of the Declaration of Helsinki. The research was designed as a non-paired observational, case control study whereby SC (the case) is compared to nBCC (the Hh tumor control). Fifteen patients with SC were included for comparison against 15 nBCC patients with a mean age of 68 and 73, years respectively. All of the SC patients had non-metastatic disease, ten nodular and five pagetoid, requiring wide excision or exenteration as treatment. Only clearly defined SC or BCC on histology were included using the Royal College of Pathologists, UK dataset \[[@CR27], [@CR28]\]. The presence of any non-nodular BCC subtype, and poorly differentiated SC where it was difficult to identify adnexal sebaceous lineage, were also excluded from the study. In addition, exclusion criteria included SC or BCC individuals with metastasis and/or recurrence. Subjects were seen at one center, Moorfields Eye Hospital.

Immunostaining procedure {#Sec4}
------------------------

Hematoxylin and eosin (H&E) staining was performed using standard methods. 3--3′-diaminobenzidine (DAB) immunostaining of 5 μm formalin-fixed, paraffin-embedded (FFPE) tissue sections was performed using a panel of commercially available antibodies for the Hh pathway proteins including PTCH1, SMO, Gli1, and Gli2 (Abcam, Cambridge, UK). Conditions for individual antibodies are summarized in Supplementary Table S[2](#MOESM3){ref-type="media"}. Tissue sections were mounted on slides, deparaffinized in xylene and then alcohol, followed by treatment with the DAKO EnVision™FLEX+ System (Dako, Glostrup, Denmark) \[[@CR29]\]. Briefly, antigen retrieval was performed using the DAKO PT LINK machine at 97°C for 20 min under alkaline (pH 9.0) or acidic (pH 6.0) conditions (Table S1). Endogenous peroxidase activity was blocked using EnVision™FLEX peroxidase-blocking reagent. Tissue was incubated with primary antibody for 30 min, followed by incubation with a secondary antibody (Envision™FLEX/HRP LINKER; 20 min) and then visualization of the primary-secondary reaction with EnVision™FLEX substrate working solution containing buffer and DAB (10 min). Sections were sealed and covered using the automated Thermo Clearview Coverslipper (Thermo Fisher Scientific Inc., Waltham, MA, USA). Positive control tissue included breast, brain, testes, and intestine for PTCH1, SMO, Gli1, and Gli2, respectively. Negative controls involved all steps excluding the primary antibody. Finally, sections were counterstained with hematoxylin using the Gemini autostainer (Thermo Fisher Scientific Inc., Waltham, MA, USA).

Immunofluorescence {#Sec5}
------------------

Immunofluorescence was used for semi-quantitative analysis of Hh pathway expression in SC in comparison to nBCC. FFPE sections were cut (5 μm) and antigen retrieval carried out as described above. Blocking of the sections occurred with 5% goat serum for 1 h followed by primary antibody staining as mentioned. Secondary antibody staining utilized AlexaFluor-568 (Invitrogen™, Life Technologies, Thermo Fisher Scientific Inc., Waltham, MA, USA). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich® MO, USA) at 1:1000 dilution to highlight the number of cells present and aid accurate semi-quantification. Coverslips were placed using VECTASHIELD® mounting medium (Vector Laboratories Inc., Burlingame, CA, USA). Negative controls omitted the primary antibody.

Confocal microscopy and fluorescence signal quantification {#Sec6}
----------------------------------------------------------

Immunofluorescence sections were examined using the Zeiss LSM710 Meta confocal laser microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) and a ZEN configuration tool (Carl Zeiss Microscopy GmbH, Jena, Germany), which is digital image-processing software that produces an output TIFF image. Negative control slides were used to remove background fluorescence and set up the acquisition conditions that subsequently remained constant throughout the imaging process. Images were taken at 200× magnification. Output TIFF images were analyzed using ImageJ (http//imagej.[nih.gov/ij](http://nih.gov/ij)) to quantify antibody expression. For semi-quantification of antibody expression, fluorescence intensity was determined in regions of interest (ROIs), ensuring a standardized area size whilst containing the same number of nuclei (averaging 18 cells) as determined by the DAPI staining. Tumor was defined as within the bulk of the tumor and at least 1 mm from the edge. Stroma was defined as non-cancerous surrounding tissue within 2 mm of the tumor edge. Furthermore, three separate ROIs were taken for each area in each sample (i.e., three tumor ROIs and three stroma ROIs in nBCC or SC samples) to obtain a mean signal for comparison.

Western blotting for antibody validation against Hh pathway {#Sec7}
-----------------------------------------------------------

Hh pathway antibodies were validated against protein lysates from LnCaP cells ectopically expressing Gli1 with resulting upregulation of the key effectors of Hh signaling \[[@CR30]\]. Negative control tissue was human wild-type fibroblasts. Pre-cast Any kD™SDS-polyacrylamide gel (Bio-Rad, Boston, MA, USA) was used to separate proteins. Twenty micrograms of protein was heated for 5 min at 95°C and mixed with 5X loading dye (100 mM Tris-GCL pH 6.8, 4% SDS; 200 mM dithiothreitol, 0.2% bromophenol blue, and 20% glycerol). Exact volume varied in order to get 20 μg of protein per lane. DualColor Prestained Protein Ladder (Bio-Rad) was used for the identification of protein size. The gel was placed into a mini-PROTEAN tetra cell system (Bio-Rad) and run for 1 h and 30 min at 60 V in 1× Nupage MES SDS running buffer (Life Technologies, Thermo Fisher Scientific Inc., Waltham, MA, USA). Protein was transferred onto an Immun-Blot™ PVDF membrane (Bio-Rad) using a Trans-Blot SD semi-dry transfer cell (Bio-Rad) and Nupage Transfer Buffer (Life Technologies) at \~8 V for 1 h. Subsequently, the membrane was blocked overnight at 4 °C in blocking solution (0.4% PBS/Tween (PBST), 5% dry milk). The following morning, the membrane was washed five times in PBST and then incubated for 2 h at room temperature with the antibody of interest (1:500 anti-PTCH, 1:200 anti-SMO, 1:1000 anti-Gli1, and 1:500 anti-Gli2). The membrane was then washed five times in PBST for 5 min, and incubated with 1:10,000 conjugated secondary anti-rabbit IgG horseradish peroxidase (HRP) (Dako, Glostrup, Denmark) for 1 h at room temperature. A further five washes of PBST for 5 min before the use of an ECL™ Prime Western blotting detection system kit (GE Healthcare, Buckinghamshire, UK). All blots were imaged under the same conditions; signal was detected using the ChemiDoc MP Imaging system (Bio-Rad) and ImageLab software (Bio-Rad). Membranes were stripped of primary antibody using Restore™ Western Blot Stripping Buffer (Thermo Fisher Scientific, Inc) at 55 °C for 30 min, washed five times for 5 min in PBST, and reprobed with 1:5000 polyclonal anti-β-actin antibody (Sigma-Aldrich, MO, USA) as a loading control for each sample.

Statistical analysis {#Sec8}
--------------------

Recorded immunofluorescence signal data for each sample is expressed as a mean ± SEM. Comparison between SC, nBCC, and normal groups was made using the Mann--Whitney*U* test. Critical values were identified for a *p* value of less than 0.05 and 0.01 and a*U* value less than these were considered to be significant.

Results {#Sec9}
=======

Hh pathway expression was detected in all 15 SC and nBCC tumors as demonstrated by the DAB immunostaining for PTCH1, SMO, Gli1, and Gli2 (Fig. [1](#Fig1){ref-type="fig"}). Western blot of LNCaP-Gli1 cells, a known hyper-expressed Hh pathway cancer cell line, demonstrated good specificity of each antibody with a clear band for the appropriate-sized protein (Fig. [2](#Fig2){ref-type="fig"}). PTCH1 expression was detected in the cytoplasm of both nBCC and SC (Fig. [1](#Fig1){ref-type="fig"} e and i, respectively) however, PTCH1 expression was markedly more pronounced in SC compared to nBCC. Similar levels of SMO were observed in both nBCC and SC (Fig. [1](#Fig1){ref-type="fig"}f and j). Gli1 and Gli2 were detected in the cytoplasm and nuclei of both nBCC and SC (Fig. [1](#Fig1){ref-type="fig"}g, k, h, and i, respectively). Gli1 expression was stronger in SC compared to nBCC, whereas similar levels of Gli2 were observed in both nBCC and SC.Fig. 1Representative pictures of Hedgehog pathway expression in positive control tissue (**a**-**d**), nBCC (**e**-**h**) and SC (**i**-**l**). **a** Breast tissue displays PTCH1 expression in the cytoplasm of the cells (*black arrows*). **b** SMO expression in testicular tissue, within the Leydig cells and seminiferous tubules cells (*black arrows*). **c** Gli1 nuclear and cytoplasmic expression in testicular tissue, particularly in the Leydig cells and seminiferous tubules (*black arrows*). **d** Nuclear expression of Gli2 in intestinal tissue, specifically localized to epithelial cells of the intestinal glands. **e** PTCH1 expression in the cytoplasm (*black arrows*) of nBCC, similar to control tissue. **f** Similar SMO expression in nBCC compared to control. **g** Increased Gli1 nuclear expression in nBCC compared to control tissue. **h** Increased Gli2 nuclear expression compared to control tissue. **i** Marked PTCH1 cytoplasmic expression in SC compared to control and nBCC. **j** Slight increase in staining of SMO in the cytoplasm (*black arrows*) of SC in contrast to nBCC. **k** Increased staining of nuclear (*black arrows*) and cytoplasmic Gli1 in SC compared to nBCC, and increased cytoplasmic expression compared to control. **l** Nuclear staining of GLi2 (*black arrows*) in SC that is similar to nBCC, but more than control tissue.*Scale bar* represents 250 μm and all images are at 200× magnification. Antibody stains for PTCH1 (**a**, **e**, **i**), SMO (**b**, **f**, **j**), Gli1 (**c**, **g**, **k**) and Gli2 (**d**, **h**, **l**).*PTCH1* Patched 1,*SMO* Smoothened,*Gli1* glioma-associated zinc transcription factor1,*Gli2* glioma-associated zinc transcription factor2Fig. 2Western-blot analysis of LnCaP-Gli1 and human wild-type fibroblasts demonstrating good specificity of each antibody with a clear band for the appropriate sized protein (20 μg per lane, *n* = 3 biological replicates). 1 = LnCaP-Gli1; 2 = Human wild-type fibroblasts.*PTCH1* Patched 1,*SMO* Smoothened,*Gli1* glioma-associated zinc transcription factor1,*Gli2* glioma-associated zinc transcription factor2

Immunofluorescence analysis was used to better quantify the amount of PTCH1, SMO, Gli1, and Gli2 expression in SC and nBCC (Fig. [3](#Fig3){ref-type="fig"}). A comparison between SC tumor and nBCC tumor was made along with physiologically activated Hh signaling (Fig. [4](#Fig4){ref-type="fig"}). PTCH1, SMO, Gli1, and Gli2 displayed higher levels of fluorescence in SC compared to nBCC (*P* \< 0.01) (Fig. [4](#Fig4){ref-type="fig"}a). PTCH1, SMO, and Gli-2 were also expressed at higher levels in SC than physiological Hh signaling (*P* \< 0.01). nBCC had similar levels of PTCH1 and Gli2 to physiologically activated Hh, but markedly lower expression of SMO and Gli1 (*P* \< 0.01). Gli1 expression is lower in both tumors compared to normal expression; however, expression is still higher in SC than nBCC (*P* \< 0.01).Fig. 3Representative pictures of Hedgehog pathway expression proteins using immunofluorescence in positive control tissue (**a** breast; **b** brain; **c** testicular; **d** intestinal), nBCC (**e**-**h**) and SC (**i**-**l**). Secondary antibody staining utilized AlexaFluor-568 and the color converted into black and white using ImageJ for pictorial purposes.*Scale bar* represents 250 μm and all images are at 200× magnification. Antibody stains for PTCH1 (**a**,**e**, **i**), SMO (**b**, **f**, **j**), Gli1 (**c**, **g**, **k**) and Gli2 (**d**,**h**,**l**).*PTCH1* Patched 1,*SMO* Smoothened,*Gli1* glioma-associated zinc transcription factor1,*Gli2* glioma-associated zinc transcription factor2Fig. 4Semi-quantification of antibody expression (*x*-axis) within **a** SC tumor, nBCC tumor, control tissue and **b** stroma of SC, nBCC, control tissue using fluorescence intensity (*y*-axis) was determined in regions of interest as delineated by microscopy, ensuring a standardized area size whilst containing the same number of nuclei as determined by DAPI staining. Each tumor sample had an average of three readings. Each*bar* represents mean values ± SEM taken from 15 nBCC, 15 SC and control tissue samples for each Hh protein. \**P* \< 0.01\*\* *P* \< 0.05.*PTCH1* Patched 1,*SMO* Smoothened,*Gli1* glioma-associated zinc transcription factor1,*Gli2* glioma-associated zinc transcription factor2

Comparison of stromal expression using immunofluorescence (Fig. [4](#Fig4){ref-type="fig"}b) showed that PTCH1, Gli1, and Gli2 were more highly expressed in the stroma of SC compared to nBCC (*P* \< 0.01). PTCH1 and Gli2 were highly upregulated in SC stroma compared to both normal expression and nBCC (*P* \< 0.01). Gli1 is less expressed in SC (*P* \< 0.05) and nBCC (*P* \< 0.01) compared to physiological Hh expression.

Discussion {#Sec10}
==========

This is the first study, as far as we are aware, that demonstrates the expression of the canonical Hh pathway, namely PTCH1, SMO, Gli1, and Gli2 in SC. Our results confirm that expression patterns are beyond normal reactivation levels, suggesting aberrant signaling.

DAB immunostaining is good for the detection of protein, however, quantification is highly subjective, for example, the use of the immunoreactivity score demonstrates significant interobserver variability has been shown in several studies \[[@CR31], [@CR32]\]. Immunofluorescence was employed to semi-quantify the amount of protein expression in the SC tumor in order to reduce this observer bias by computational counting along with the removal of background noise. Nevertheless, any immunohistochemistry method has many variables during processing, so relative expression to another tumor processed in an identical fashion is a more robust way of analyzing overall expression. In order to do this, a known aberrant Hh pathway tumor, nBCC, was selected for comparison \[[@CR33]\]. Hh signaling is normally switched off in the majority of adult tissues, however, some do transiently express Hh. These normal tissue samples represent physiologically expressed Hh and were also used for comparison to determine if expression was simply re-activation or aberrant overexpression.

Levels of expression within SC tumor were significantly higher than those observed in nBCC. Furthermore, these levels were more than physiological re-activation, except for Gli1, which was less than in normal Hh-expressing tissue. It is estimated that up to 25% of tumors depend on the Hh pathway activity for growth \[[@CR34]\]. Nodular BCC is a slow-growing cancer that metastasizes rarely \[[@CR33]\]. In contrast, SC is locally aggressive, metastasizes and has a risk of mortality of up to 29% \[[@CR8]--[@CR10]\]. Thus, it is possible that the increased Hh expression seen in SC accounts for its more aggressive nature compared to nBCC. The exact role of Hh expression in SC cannot be discerned from this study alone, as Hh signaling has been implicated in tumorigenesis, growth, progression, local invasion, and metastasis \[[@CR17]--[@CR20]\].

The stroma of SC was found to express components of the Hh pathway, and in particular, Gli2 was considerably more upregulated. Cancer can modify the surrounding non-malignant tissue to facilitate local invasion \[[@CR26]\]. Gli2 is an activator of the Hh pathway and plays a critical role in medulloblastoma tumorigenesis, with loss of Gli2 expression preventing the tumor formation \[[@CR35], [@CR36]\]. Moreover, higher levels of Gli2 are associated with a loss of the cell adhesion molecule E-cadherin in melanoma cell lines with increased capacity for local invasion; higher levels correlated with the most aggressive tumors \[[@CR37], [@CR38]\]. In contrast, knockdown models of Gli2 demonstrated reduced tumor growth in prostatic in vivo models \[[@CR39]\]. Hh expression as a lone stimulator is unlikely and crosstalk with multiple pathways can occur. For example, transforming growth factor-β (TGF-β) has been shown to promote Gli2 expression and is involved in tumor progression and metastasis \[[@CR40]\].

Activation of the Hh pathway in SC raises the possibility of medical treatment for these tumors, and potentially avoiding exenteration. Attenuation of the Hh pathway has been shown to be successful by using SMO inhibitors, with vismodegib presently being the most widely used compound in clinical trials and used for locally advanced or metastatic BCC \[[@CR41], [@CR42]\]. Furthermore, neoadjuvant treatment with vismodegib to reduce tumor size in BCC \[[@CR43]\] has been successful in making the tumor more amenable to surgery. Vismodegib has been trialed in a variety of cancers, including pancreatic, ovarian cancer, breast and prostate cancers, and other SMO inhibitors are emerging such as sonidegib and BMS-833923 \[[@CR44]\]. Gli antagonists have been developed too, and this may be a more promising level to block the pathway, especially Gli2 and could be used in combination to either block Hh at multiple levels or activated pathways \[[@CR45]\]. It is possible that these agents could be efficacious in advanced or metastatic SC and if such a neoadjuvant response could be replicated, it may allow the preservation of sight by averting the need for a blinding exenteration.

Limitations of the study include a small sample size, although as SC is a rare tumor in Western countries, it is difficult to obtain high numbers. Further studies are required to identify the role of each protein in relation to SC behavior and could include tumorigenesis, propagation, local invasion, migration, or metastasis.

Hedgehog pathway activation occurs in periocular SC, in both the tumor and surrounding stromal tissue at a higher level than nBCC, a known Hh-driven tumor. The timing for any treatment modification of the Hh pathway would be dependent on its specific role in the pathogenesis of SC, and further studies are required to determine this.
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